Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2010

View Archived Issues

QTc interval is prolonged in myotonic dystrophy type 1 / News in Context

Phase II data show efficacy of Gilead Sciences' Quad anti-HIV regimen through 48 weeks

TransVax reduces cytomegalovirus viremia in phase II trial

SAR-707 reveals limitations of acyl-CoA desaturase inhibition in metabolic disorders

Chitosan-GP is efficacious in ongoing trial in patients with articular cartilage lesions

Acucela and Otsuka Pharma to codevelop and -promote OPA-6566 for glaucoma

Cylene begins phase I trial of CX-4945 in multiple myeloma

FDA grants orphan drug status for iCo-009 in visceral leishmaniasis

Phase III trial of Budesonide MMX in ulcerative colitis meets primary endpoint

Prefilled syringes of Relistor approved in U.S., E.U. and Canada

Medivation and Astellas begin phase III MDV-3100 trial in advanced prostate cancer

Astellas files for Japanese approval of darexaban for VTE prevention

Enrollment complete in phase IIa trial of XOMA-052 in type 2 diabetes

Zeria submits acotiamide for approval in Japan to treat functional dyspepsia

Unibioscreen claims novel cardiotonic steroid derivatives

Baxter obtains approval in Austria for Preflucel influenza vaccine

New voltage-gated potassium K(V)7.2/3 channel modulators described

Cleveland BioLabs reports on second safety study of CBLB-502

AstraZeneca begins enrollment in phase III OSKIRA program for fostamatinib in RA

Novel benzoxazinone derivatives claimed by NeuroSearch

Conbriza is approved in Spain for postmenopausal osteoporosis

Astellas and UMN Pharma enter definitive agreement for flu vaccines

Pieris, sanofi-aventis and Sanofi Pasteur to develop anticalin therapeutics

Astellas Pharma patents new 17-beta-HSD 5 inhibitors

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...